Home » Stocks » AUTL

Autolus Therapeutics PLC (AUTL)

Stock Price: $8.80 USD -0.10 (-1.12%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $8.75 -0.05 (-0.57%) Jan 26, 5:51 PM
Market Cap 460.23M
Revenue (ttm) 1.62M
Net Income (ttm) -140.18M
Shares Out 52.09M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $8.80
Previous Close $8.90
Change ($) -0.10
Change (%) -1.12%
Day's Open 8.99
Day's Range 8.70 - 9.12
Day's Volume 153,342
52-Week Range 4.20 - 16.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

• Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), with full data from the AUTO1-AL1 study expected in 2022 •  Company intends ...

GlobeNewsWire - 3 weeks ago

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today anno...

GlobeNewsWire - 1 month ago

AUTO3 continues to show a differentiated product profile supporting outpatient administration

GlobeNewsWire - 1 month ago

Updated data from the ALLCAR study suggests AUTO1's potential for transformational activity in adult patients with r/r ALL

Zacks Investment Research - 1 month ago

Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Seeking Alpha - 2 months ago

Autolus - a developer of next-generation programmed T cell therapies - has shown continued progress in advancing its anti-cancer pipeline. AUTO1 has entered a pivotal trial for ALL and may ach...

GlobeNewsWire - 2 months ago

LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today anno...

Seeking Alpha - 2 months ago

Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today anno...

GlobeNewsWire - 4 months ago

-  AUTO3 shows promise of a highly differentiated product profile

GlobeNewsWire - 4 months ago

LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today a...

Seeking Alpha - 5 months ago

Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

- Conference call to be held on August 6, 2020 at 8:30 am EDT/1:30 pm BST - - Conference call to be held on August 6, 2020 at 8:30 am EDT/1:30 pm BST -

GlobeNewsWire - 5 months ago

Dr. Jay T. Backstrom appointed to board of directors Dr. Jay T. Backstrom appointed to board of directors

Zacks Investment Research - 7 months ago

Autolus Therapeutics plc (AUTL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

GlobeNewsWire - 7 months ago

- AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of TRBC2 by a novel CAR T candidate

Zacks Investment Research - 7 months ago

Is (AUTL) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 7 months ago

Pivotal AUTO1 study in adult ALL patients enrolling

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Autolus Therapeutics.

Zacks Investment Research - 8 months ago

Autolus Therapeutics (AUTL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock ...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Autolus Therapeutics

Seeking Alpha - 8 months ago

Autolus Therapeutics Plc (AUTL) CEO Christian Itin on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

Shares of Autolus Therapeutics (NASDAQ:AUTL) were unchanged at $10.28 after the company reported Q1 results.

GlobeNewsWire - 9 months ago

LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the ...

Seeking Alpha - 10 months ago

Autolus Therapeutics (AUTL) CEO Christian Itin on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

- Initial data show encouraging clinical activity with manageable safety profile - No neurotoxicity observed to date in patients treated with AUTO3 + pembrolizumab

GlobeNewsWire - 11 months ago

LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today an...

The Motley Fool - 1 year ago

Investors are reacting negatively to the biotech's public stock offering.

GlobeNewsWire - 1 year ago

LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today an...

GlobeNewsWire - 1 year ago

LONDON, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today an...

GuruFocus - 1 year ago

Wall Street issued positive recommendation ratings for Autolus Therapeutics plc (NASDAQ:AUTL) and Jianpu Technology Inc (NYSE:JT) even though their stocks plunged over the past year through Tu...

Other stocks mentioned: JT
Zacks Investment Research - 1 year ago

Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.

Other stocks mentioned: ALKS, ATRA, INVA, RTRX
GlobeNewsWire - 1 year ago

Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T

GlobeNewsWire - 1 year ago

AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome  

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Autolus Therapeutics.

GlobeNewsWire - 1 year ago

LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the t...

GlobeNewsWire - 1 year ago

Enhancing the anti-tumor potential of CAR T cells for the treatment of solid tumors Enhancing the anti-tumor potential of CAR T cells for the treatment of solid tumors

Seeking Alpha - 1 year ago

Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the t...

The Motley Fool - 1 year ago

Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.

Other stocks mentioned: MRTX, NKTR
GlobeNewsWire - 1 year ago

Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome

GlobeNewsWire - 1 year ago

LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today an...

Seeking Alpha - 1 year ago

Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Seeking Alpha - 1 year ago

Autolus Therapeutics PLC. (AUTL) CEO Christian Itin on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Industry
Biotechnology
IPO Date
Jun 22, 2018
CEO
Dr. Christian Martin Itin
Employees
290
Stock Exchange
NASDAQ
Ticker Symbol
AUTL
Full Company Profile

Financial Performance

In 2019, AUTL's revenue was $2.91 million, an increase of 106.68% compared to the previous year's $1.41 million. Losses were -$123.85 million, 176.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is 20.78, which is an increase of 136.14% from the latest price.

Price Target
$20.78
(136.14% upside)
Analyst Consensus: Buy